Codiak BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
10 mars 2022 16h01 HE
|
Codiak BioSciences, Inc.
– Reported positive initial data from exoSTING™ clinical trial; on track to provide data from all dose escalation cohorts in late 1H 2022 – – Investigational New Drug (IND) application cleared for...
Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science Advances
18 févr. 2022 14h00 HE
|
Codiak BioSciences, Inc.
– Unprecedented monotherapy activity via macrophage reprogramming in preclinical models – – Phase 1 study expected to begin in 1H 2022 – CAMBRIDGE, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Codiak...
Codiak BioSciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
06 janv. 2022 09h00 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
Codiak’s Engineered Exosomes Promote T Cell and Antibody Responses to SARS-CoV-2 in vivo, Supporting the Potential for a Broadly Protective Pan-Beta Coronavirus and Variant Vaccine
02 déc. 2021 08h30 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based...
Codiak BioSciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
01 déc. 2021 16h05 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
Codiak BioSciences Announces FDA Clearance of IND for exoASO™-STAT6; Patient Dosing Expected 1H 2022
30 nov. 2021 08h30 HE
|
Codiak BioSciences, Inc.
– Codiak’s first engineered exosome therapeutic candidate for systemic administration – – Single agent anti-tumor effect observed in preclinical models via macrophage reprogramming – – Phase 1...
Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts
16 nov. 2021 06h45 HE
|
Codiak BioSciences, Inc.
– exoSTING resulted in localized STING pathway activation and dose-dependent immune activation – – Intratumoral administration of exoSTING was well tolerated and demonstrated tumor retention, no...
New Preclinical Data at SITC 2021 Show Broad Potential Utility of Codiak’s Engineered Exosomes
12 nov. 2021 07h00 HE
|
Codiak BioSciences, Inc.
– exoSTING™ monotherapy suppressed tumor growth and improved overall survival in a preclinical model of leptomeningeal disease, an aggressive metastasis of cancer to the central nervous system – –...
Codiak BioSciences Reports Third Quarter 2021 Financial Results and Recent Operational Progress
04 nov. 2021 16h01 HE
|
Codiak BioSciences, Inc.
– Announced strategic long-term exosome manufacturing collaboration with Lonza – – Initial data readout from exoSTING™ clinical trial expected in Q4 2021; initial data from exoIL-12™ trial in...
Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic Collaboration
02 nov. 2021 08h00 HE
|
Codiak BioSciences, Inc.
Lonza to acquire and operate Codiak's Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak’s pipelineLonza and Codiak to establish a Center of Excellence focused on...